Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 1.00 |
| ▸ | BRAF | P15056 | 13/20 | 0.77 |
| ▸ | EGFR | P00533 | 11/20 | 0.73 |
| ▸ | CSF1R | P07333 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080656 | 1.00 | KIT (1.00) | KITBRAFEGFRCSF1RABL1 | |
| SCHEMBL29493482 | 1.00 | KIT (1.00) | KITBRAFEGFRCSF1RABL1 | |
| SCHEMBL588917 | 0.96 | KIT (0.93) | KITBRAFEGFRCSF1R | |
| SCHEMBL590507 | 0.93 | KIT (0.86) | KITBRAFEGFRABL1 | |
| SCHEMBL16236899 | 0.92 | KIT (0.86) | KITBRAFEGFR | |
| SCHEMBL27933497 | 0.91 | KIT (0.84) | KITBRAFEGFRCSF1R | |
| SCHEMBL12871531 | 0.91 | KIT (0.84) | KITBRAFEGFRABL1 | |
| SCHEMBL12988951 | 0.91 | KIT (0.83) | KITBRAFEGFR | |
| SCHEMBL19500735 | 0.90 | KIT (0.82) | KITBRAFEGFRCSF1R | |
| SCHEMBL4100085 | 0.90 | KIT (0.81) | KITBRAFEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044432-B | Bicyclic heteroaryl compounds | 阿里亚德医药股份有限公司 | 2016-08-03 | — | — | CN | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3795571-B1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2024-05-08 | — | — | EP | disclosed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| EP-3808746-B1 | N-[3-[2-[8-[(1H-PYRAZOL-4-YL)AMINO]IMIDAZO[1,2-A]PYRAZIN-3-YL]ETHYNYL]PHENYL]-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SHENZHEN TARGETRX INC (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022149855-A1 | HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-110272426-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-101489558-A | Acetylenic heteroaryl compounds | ARIAD PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-101490053-A | Monocyclic Heteroaryl Compounds | ARIAD PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| CN-101389338-A | Bicyclic heteroaryl compounds | ARIAD PHARMA INC (US) | 2009-03-18 | — | — | CN | disclosed |
| EP-2023933-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133560-A9 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | KIT 813/4885BRAF 2370/4885EGFR 1955/4885 |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | KIT 3086/4885BRAF 3990/4885EGFR 2495/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | KIT 824/4885BRAF 2396/4885EGFR 2266/4885 |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | ALK, WEE1, WEE2 | KIT 625/4885BRAF 5/4885EGFR 438/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | KIT 824/4885BRAF 2396/4885EGFR 2266/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | KIT 537/4885BRAF 58/4885EGFR 457/4885 |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | ALK, BRAF, DSTYK | KIT 857/4885BRAF 2/4885EGFR 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.